MaxCyte Lifts 2026 Revenue Guidance Excluding Akron Acquisition

The Tip Desk · November 10, 2026 · 3 min read

Third-quarter revenue reached $10.2 million as the company raised full-year 2026 revenue guidance to at least $34.5 million, excluding the impact of the Akron acquisition, and agreed to buy Akron Bio for $151.8 million.

MaxCyte, Inc. (MXCT), a cell-engineering company, reported third-quarter 2026 revenue of $10.2 million, up 49% from $6.8 million a year earlier, after a 15% year-over-year decline in the second quarter.

Excluding the impact of the Akron acquisition, the company raised full-year 2026 total revenue guidance to at least $34.5 million, from October guidance of approximately $34 million, and said it now expects approximately 15% year-over-year core revenue growth in the second half of 2026.

Core business revenue was $8.2 million in the third quarter, reversing a 21% year-over-year decline in the second quarter. Strategic Platform License Program-related revenue was $2.0 million, including $1.0 million of milestones and $0.99 million of royalties, versus $0.4 million a year earlier.

Instruments were the largest swing inside the core business: $2.78 million, up 102% from $1.38 million a year earlier. The company said third-quarter outperformance was driven by accelerated instrument purchasing from a large customer originally expected in the fourth quarter. PAs and Consumables were $3.09 million, up 20%. Licenses were $1.97 million. Assay Service was $43 thousand and Other revenue $276 thousand.

Gross profit was $8.5 million, or an 83% gross margin. Non-GAAP adjusted gross margin, excluding SPL revenue and inventory reserves, was 80%. Operating expenses were $14.5 million, down from $19.4 million a year earlier, when a $3.1 million restructuring charge did not recur. Net loss was $4.8 million, or $0.05 a share, compared with a $12.4 million net loss, or $0.12 a share, a year earlier. EBITDA loss was $5.1 million.

Research and development expense was $2.87 million. Sales and marketing was $4.21 million. General and administrative was $6.55 million.

Total SPL agreements were 28 as of September 30, 2026, including 13 programs in the clinic and one commercial program. President and CEO Maher Masoud said SPL partners have more late-stage programs than ever before, including two pivotal trials that could result in approvals as early as next year. In July the company announced a multi-platform technology license partnership with Genentech.

Cash, cash equivalents and investments were $132.7 million as of September 30, 2026, down from $141.9 million as of June 30.

On November 10, MaxCyte announced a definitive agreement to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management for total consideration of $151.8 million, including $105.0 million in cash, 20,639,733 shares valued at about $26.8 million, and $20.0 million of guaranteed deferred payments due in January 2028 and January 2029. Akron, a supplier of GMP-grade reagents and ancillary materials for cell therapy manufacturing, is expected to generate about $28 million in 2026 revenue and $7 million to $8 million in EBITDA. The company said the deal is expected to nearly double MaxCyte’s revenue base.

The transaction is expected to close before the end of 2026. MaxCyte secured a new MidCap Financial credit facility of up to $75.0 million, including a $55.0 million term loan and a $20.0 million revolving credit facility. Assuming Akron closes, the company expects about $40.0 million to $45.0 million in cash, cash equivalents and investments at year-end 2026 after the cash consideration, $22.0 million drawn under the facility, and deal expenses.

Masoud said combining MaxCyte and Akron will expand the commercial opportunity and strengthen the financial profile. Akron is expected to continue under its existing brand.